The Notch signaling pathway as a mediator of tumor survival

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1420-1430

  Capaccione, Kathleen M ^a   Pine, Sharon R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; BIM PROTEIN; CISPLATIN; CYCLIN D1; DOCETAXEL; GEFITINIB; I KAPPA B; JAGGED1; MK 0752; MYC PROTEIN; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; OXALIPLATIN; PRESENILIN 2; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; SURVIVIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HEY 1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL FATE; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME TRANSLOCATION; COLON CANCER; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG STRUCTURE; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LIGAND BINDING; LUNG CANCER; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TUMOR CELL; WNT SIGNALING PATHWAY;

AMYLOID PRECURSOR PROTEIN SECRETASES; CELL PROLIFERATION; DIPEPTIDES; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PLATINUM COMPOUNDS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880306937     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt127     Document Type: Article

References (140)

1. Mohr, O.L. (1919) Character changes caused by mutation of an entire region of a chromosome in Drosophila. Genetics, 4, 275-282.
2. Kidd, S. et al. (1986) Sequence of the notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors. Mol. Cell. Biol., 6, 3094-3108.
3. Wharton, K.A. et al. (1985) Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell, 43(3 Pt 2), 567-581.
4. Kurooka, H. et al. (1998) Roles of the ankyrin repeats and C-terminal region of the mouse notch1 intracellular region. Nucleic Acids Res., 26, 5448-5455.
5. Mumm, J.S. et al. (2000) Notch signaling: from the outside in. Dev. Biol., 228, 151-165.
6. Fortini, M.E. (2009) Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell, 16, 633-647.
7. Artavanis-Tsakonas, S. et al. (1995) Notch signaling. Science, 268, 225-232.
8. Miele, L. (2006) Notch signaling. Clin. Cancer Res., 12, 1074-1079.
9. Logeat, F. et al. (1998) The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc. Natl Acad. Sci. USA, 95, 8108-8112.
10. Blaumueller, C.M. et al. (1997) Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell, 90, 281-291.
11. Rand, M.D. et al. (2000) Calcium depletion dissociates and activates heterodimeric notch receptors. Mol. Cell. Biol., 20, 1825-1835.
12. Gordon, W.R. et al. (2007) Structural basis for autoinhibition of Notch. Nat. Struct. Mol. Biol., 14, 295-300.
13. Heitzler, P. et al. (1991) The choice of cell fate in the epidermis of Drosophila. Cell, 64, 1083-1092.
14. Heitzler, P. et al. (1993) Altered epidermal growth
15. Chitnis, A.B. (1995) The role of Notch in lateral inhibition and cell fate specification. Mol. Cell. Neurosci., 6, 311-321.
16. Lu, J. et al. (2013) Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell, 23, 171-185.
17. Brou, C. et al. (2000) A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell, 5, 207-216.
18. Fortini, M.E. (2001) Notch and presenilin: a proteolytic mechanism emerges. Curr. Opin. Cell Biol., 13, 627-634.
19. Francis, R. et al. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell, 3, 85-97.
20. Goutte, C. et al. (2002) APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl Acad. Sci. USA, 99, 775-779.
21. Yu, G. et al. (2000) Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature, 407, 48-54.
22. De Strooper, B. (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. Neuron, 38, 9-12.
23. Borggrefe, T. et al. (2009) The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell. Mol. Life Sci., 66, 1631-1646.
24. Jarriault, S. et al. (1995) Signalling downstream of activated mammalian Notch. Nature, 377, 355-358.
25. Nellesen, D.T. et al. (1999) Discrete enhancer elements mediate selective responsiveness of enhancer of split complex genes to common transcriptional activators. Dev. Biol., 213, 33-53.
26. Tamura, K. et al. (1995) Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H). Curr. Biol., 5, 1416-1423.
27. Tun, T. et al. (1994) Recognition sequence of a highly conserved DNA binding protein RBP-J kappa. Nucleic Acids Res., 22, 965-971.
28. Weng, A.P. et al. (2006) c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev., 20, 2096-2109.
29. Kao, H.Y. et al. (1998) A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev., 12, 2269-2277.
30. Jarriault, S. et al. (1998) Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Mol. Cell. Biol., 18, 7423-7431.
31. Bailey, A.M. et al. (1995) Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev., 9, 2609-2622.
32. Fisher, A.L. et al. (1996) The WRPW motif of the hairy-related basic helix-loop-helix repressor proteins acts as a 4-amino-acid transcription repression and protein-protein interaction domain. Mol. Cell. Biol., 16, 2670-2677.
33. Fischer, A. et al. (2007) Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res., 35, 4583-4596.
34. Bjornson, C.R. et al. (2012) Notch signaling is necessary to maintain quiescence in adult muscle stem cells. Stem Cells, 30, 232-242.
35. Mourikis, P. et al. (2012) A critical requirement for notch signaling in maintenance of the quiescent skeletal muscle stem cell state. Stem Cells, 30, 243-252.
36. Vasyutina, E. et al. (2007) RBP-J (Rbpsuh) is essential to maintain muscle progenitor cells and to generate satellite cells. Proc. Natl Acad. Sci. USA, 104, 4443-4448.
37. Nickoloff, B.J. et al. (2002) Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ., 9, 842-855.
38. Yin, L. et al. (2010) Notch signaling: emerging molecular targets for cancer therapy. Biochem. Pharmacol., 80, 690-701.
39. Ronchini, C. et al. (2001) Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol. Cell. Biol., 21, 5925-5934.
40. Lamar, E. et al. (2001) Nrarp is a novel intracellular component of the Notch signaling pathway. Genes Dev., 15, 1885-1899.
41. Vilimas, T. et al. (2007) Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med., 13, 70-77.
42. Rangarajan, A. et al. (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J., 20, 3427-3436.
43. Reizis, B. et al. (2002) Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev., 16, 295-300.
44. Klinakis, A. et al. (2006) Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl Acad. Sci. USA, 103, 9262-9267.
45. Palomero, T. et al. (2006) Notch1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA, 103, 18261-18266.
46. Eliasz, S. et al. (2010) Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene, 29, 2488-2498.
47. Chen, Y. et al. (2011) Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol. Ther., 11, 14-21.
48. Niessen, K. et al. (2008) Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J. Cell Biol., 182, 315-325.
49. Reynolds, T.C. et al. (1987) Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms. Cell, 50, 107-117.
50. Ellisen, L.W. et al. (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66, 649-661.
51. Weng, A.P. et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science, 306, 269-271.
52. Lin, Y.W. et al. (2006) Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood, 107, 2540-2543.
53. Xu, X. et al. (2011) Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med. Oncol., 28 (suppl. 1), S483-S489.
54. Zhang, J. et al. (2012) Prognostic impact of d-like ligand 4 and Notch1 in acute myeloid leukemia. Oncol. Rep., 28, 1503-1511.
55. Gallahan, D. et al. (1987) A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J. Virol., 61, 218-220.
56. Gallahan, D. et al. (1997) The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene, 14, 1883-1890.
57. Uyttendaele, H. et al. (1996) Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development, 122, 2251-2259.
58. Stylianou, S. et al. (2006) Aberrant activation of notch signaling in human breast cancer. Cancer Res., 66, 1517-1525.
59. Reedijk, M. et al. (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res., 65, 8530-8537.
60. Dickson, B.C. et al. (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod. Pathol., 20, 685-693.
61. Reedijk, M. et al. (2008) JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res. Treat., 111, 439-448.
62. Westhoff, B. et al. (2009) Alterations of the Notch pathway in lung cancer. Proc. Natl Acad. Sci. USA, 106, 22293-22298.
63. Zheng, Q. et al. (2007) Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncol. Rep., 17, 847-852.
64. Pine, S.R. et al. (2008) Lung cancer stem cells. Dis. Markers, 24, 257-266.
65. Chen, Y. et al. (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res., 67, 7954-7959.
66. Allen, T.D. et al. (2011) Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res., 71, 6010-6018.
67. Dang, T.P. et al. (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl. Cancer Inst., 92, 1355-1357.
68. Haruki, N. et al. (2005) Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res., 65, 3555-3561.
69. Konishi, J. et al. (2007) Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res., 67, 8051-8057.
70. Konishi, J. et al. (2010) Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene, 29, 589-596.
71. Lin, L. et al. (2010) Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res., 70, 632-638.
72. Donnem, T. et al. (2010) Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer, 116, 5676-5685.
73. Purow, B.W. et al. (2005) Expression of Notch-1 and its ligands, Deltalike- 1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res., 65, 2353-2363.
74. Chen, L. et al. (2012) The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis, 33, 2276-2282.
75. Li, J. et al. (2011) Notch1 is an independent prognostic factor for patients with glioma. J. Surg. Oncol., 103, 813-817.
76. Koch, U. et al. (2007) Notch and cancer: a double-edged sword. Cell. Mol. Life Sci., 64, 2746-2762.
77. Nicolas, M. et al. (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet., 33, 416-421.
78. Carlén, M. et al. (2009) Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat. Neurosci., 12, 259-267.
79. Pellegrinet, L. et al. (2011) Dll1-and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology, 140, 1230-1240.e1.
80. Gal, H. et al. (2006) Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia, 20, 2147-2154.
81. Tatarek, J. et al. (2011) Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood, 118, 1579-1590.
82. Dontu, G. et al. (2004) Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res., 6, R605-R615.
83. Simmons, M.J. et al. (2012) NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res., 14, R126.
84. Won, H.Y. et al. (2012) Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J., 26, 5002-5013.
85. Harrison, H. et al. (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res., 70, 709-718.
86. Singh, S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401.
87. Singh, S.K. et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res., 63, 5821-5828.
88. Gürsel, D.B. et al. (2012) The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery, 70, N19-N21.
89. Ignatova, T.N. et al. (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia, 39, 193-206.
90. Lee, J. et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9, 391-403.
91. Fan, X. et al. (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 28, 5-16.
92. Zhu, T.S. et al. (2011) Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res., 71, 6061-6072.
93. Hovinga, K.E. et al. (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells, 28, 1019-1029.
94. Fan, X. et al. (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 66, 7445-7452.
95. Sikandar, S.S. et al. (2010) NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res., 70, 1469-1478.
96. Park, J.T. et al. (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am. J. Pathol., 177, 1087-1094.
97. Eramo, A. et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 15, 504-514.
98. Liu, Y.P. et al. (2013) Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res., 73, 406-416.
99. Hassan, K.A. et al. (2013) Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res., 19, 1972-1980.
100. Nishina, S. et al. (2011) Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol. Rep., 26, 523-531.
101. Chen, J. et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488, 522-526.
102. Driessens, G. et al. (2012) Defining the mode of tumour growth by clonal analysis. Nature, 488, 527-530.
103. Schepers, A.G. et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science, 337, 730-735.
104. Jing, Y. et al. (2011) Epithelial-mesenchymal transition in tumor microenvironment. Cell Biosci., 1, 29.
105. Saad, S. et al. (2010) Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int. J. Biochem. Cell Biol., 42, 1115-1122.
106. Stoyianni, A. et al. (2012) Immunohistochemical study of the epithelial- mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res., 32, 1273-1281.
107. Bao, B. et al. (2011) Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett., 307, 26-36.
108. Xie, M. et al. (2012) Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem., 113, 1501-1513.
109. McAuliffe, S.M. et al. (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl Acad. Sci. USA, 109, E2939-E2948.
110. Ye, Q.F. et al. (2012) siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac. J. Cancer Prev., 13, 2485-2489.
111. Meng, R.D. et al. (2009) gamma-Secretase inhibitors abrogate oxaliplatin- induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res., 69, 573-582.
112. Gilbert, C.A. et al. (2010) Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res., 70, 6870-6879.
113. Wang, J. et al. (2010) Notch promotes radioresistance of glioma stem cells. Stem Cells, 28, 17-28.
114. Mizuma, M. et al. (2012) The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol. Cancer Ther., 11, 1999-2009.
115. Wong, G.T. et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem., 279, 12876-12882.
116. Abcam. DAPT. http://www.abcam.com/DAPT-ab120633.html (29 April 2013, date last accessed).
117. Selleck. Ro4929097. http://www.selleckchem.com/products/RO4929097. html (29 April 2013, date last accessed).
118. Kondratyev, M. et al. (2012) Gamma-secretase inhibitors target tumorinitiating cells in a mouse model of ERBB2 breast cancer. Oncogene, 31, 93-103.
119. Maraver, A. et al. (2012) Therapeutic effect of ?-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell, 22, 222-234.
120. Hemming, M.L. et al. (2008) Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol., 6, e257.
121. Beel, A.J. et al. (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell. Mol. Life Sci., 65, 1311-1334.
122. NIH. (2012) Gamma secretase inhibitor. http://clinicaltrials.gov/ct2/results?term=gamma+secretase+inhibitor&Search=Search.
123. NIH. (2013) Notch inhibitor cancer. http://www.clinicaltrials.gov/ct2/res ults?term=notch+inhibitor+cancer&Search=Search.
124. H. Lee Moffitt Cancer Center and Research Institute. (2012) An open-label study of RO4929097 in metastatic colorectal cancer (NCT01116687).
125. Krop, I. et al. (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol., 30, 2307-2313.
126. Samon, J.B. et al. (2012) Preclinical analysis of the ?-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol. Cancer Ther., 11, 1565-1575.
127. Children's Oncology Group. (2012) Gamma-secretase inhibitor RO4929097 in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia (NCT01088763).
128. Wu, Y. et al. (2010) Therapeutic antibody targeting of individual Notch receptors. Nature, 464, 1052-1057.
129. Falk, R. et al. (2012) Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods, 58, 69-78.
130. Thurston, G. et al. (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer, 7, 327-331.
131. Noguera-Troise, I. et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444, 1032-1037.
132. Jenkins, D.W. et al. (2012) MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol. Cancer Ther., 11, 1650-1660.
133. MedImmune (2010). A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of MEDI0639 in advanced solid tumors (NCT01577745).
134. Liu, S.K. et al. (2011) Delta-like ligand 4-notch blockade and tumor radiation response. J. Natl Cancer Inst., 103, 1778-1798.
135. Yan, M. et al. (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature, 463, E6-E7.
136. Poirault-Chassac, S. et al. (2010) Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood, 116, 5670-5678.
137. Wang, Z. et al. (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer, 106, 2503-2513.
138. Wang, Z. et al. (2009) Emerging role of Notch in stem cells and cancer. Cancer Lett., 279, 8-12.
139. Howells, L.M. et al. (2011) Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int. J. Cancer, 129, 476-486.
140. Li, Y. et al. (2012) Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. FEBS J., 279, 2247-2259.